IN8bio’s INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed Glioblastoma
20 nov. 2023 07h00 HE
|
IN8bio, Inc
All patients treated with INB-200 who completed mandated doses to date have exceeded a progression-free survival (PFS) of seven months Most patients exceeded the expected median PFS based on age and...
IN8bio to Present Data Highlighting Potential of INB-200 and INB-400 to Treat Patients with Newly Diagnosed Glioblastoma Multiforme at Society for Neuro-Oncology 28th Annual Meeting
10 nov. 2023 07h00 HE
|
IN8bio, Inc
Company will present “late-breaker” poster detailing updated clinical data from Phase 1 trial of INB-200 Company-sponsored Phase 2 trial of INB-400 to be showcased in Trials-in-Progress (TIPs) poster...
IN8bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
09 nov. 2023 16h00 HE
|
IN8bio, Inc
Completed dose escalation in Phase 1 Trial of INB-100 with updated clinical data to be presented at the American Society of Hematology (ASH) Annual Meeting on December 11, 2023 (Abstract Number:...
IN8bio Presents Biologic Correlative Data from the INB-200 Phase 1 Trial in Newly Diagnosed Glioblastoma at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
06 nov. 2023 08h00 HE
|
IN8bio, Inc
Data demonstrate the ability of single and repeat doses of INB-200, DeltEx drug-resistant immunotherapy (DRI) gamma-delta T cell therapy, to induce T cell persistence and a sustained immune response.A...
IN8bio Presents Positive Data Update from Induced Pluripotent Stem Cell (iPSC) Platform at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
03 nov. 2023 12h00 HE
|
IN8bio, Inc
This data represents a step forward in developing next-generation ‘off-the-shelf’ iPSC derived gamma-delta T cells. Our proprietary expansion methods are serum and feeder-free and have the potential...
IN8bio to Present New Positive Data from Phase 1 Trial of INB-100 at 2023 American Society of Hematology (ASH) Annual Meeting
02 nov. 2023 09h17 HE
|
IN8bio, Inc
New data on the completed dose-escalation of this Phase 1 trial highlights promising efficacy of INB-100 in patients with hematologic malignancies; updated data on durability of responses and...
IN8bio to Participate at the 2023 Truist Securities BioPharma Symposium
01 nov. 2023 08h00 HE
|
IN8bio, Inc
NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced...
IN8bio Completes Dose Escalation in Phase 1 Trial of INB-100, a Potential First-in-Class Gamma-Delta T Cell Therapy for the Treatment of Leukemias, and Initiates Enrollment for the Phase 2 Trial of INB-400 in Newly Diagnosed Glioblastoma
12 oct. 2023 08h00 HE
|
IN8bio, Inc
Enrollment is now open in the company-sponsored Phase 2 clinical trial of INB-400 in patients with newly diagnosed glioblastoma multiforme (GBM). Enrollment completed in the dose escalation phase...
IN8bio Announces Presentations at the Society for Immunology of Cancer (SITC) 38th Annual Meeting
29 sept. 2023 08h00 HE
|
IN8bio, Inc
NEW YORK, Sept. 29, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced two...
IN8bio to Host Research & Development Day on its Gamma-Delta T cell Therapies on Thursday, October 12, 2023 in New York City
26 sept. 2023 08h00 HE
|
IN8bio, Inc
Management presentations will highlight IN8bio’s clinical and scientific programs, including upcoming data releases at several upcoming fall medical meetingsFeatured presentations by clinical thought...